It has been shown to function as a tumor suppressor by inhibiting the NF-κB pathway in various cancers, including breast cancer (Liu et al., 2015; Wu et al., 2018), melanoma (Bian et al., 2017), non-small cell lung cancer (Lu et al., 2017), nasopharyngeal carcinoma (Zhang et al., 2019), laryngeal cancer (Yang et al., 2018), and ESCC (Lu et al., 2018). The gene discussed is NFKB1; the disease is breast cancer.